Monday, 26 Jun 2017


Datesort ascending Type Title Save
08 Jun 2016 Social Secukinumab data presented at EULAR; Novartis plans H2H trial of Cosentyx & Humira; details to follow
08 Jun 2016 News EULAR: Tofacitinib Effective in Ankylosing Spondylitis
27 May 2016 Social Review of 164 SAPHO pts. Most common:palmoplantar pustulosis > severe acne, Chest wall pain > LBP, 70% ^CRP, 2% B27+
19 May 2016 Social @DrPetryna Calprotectin (stool or serum) a biomarker in IBD, used to identify bowel inflammation in SpA patients
12 May 2016 News Secukinumab Improves Patient-Reported Outcomes in Psoriatic Arthritis (FUTURE 1)
12 May 2016 Social CORRONA & NPF sign on for a postmarketing safety registry of >4000 Psoriasis pts on Taltz (ixekizumab)
09 May 2016 Social Genetic overlap betw anklyosing spondylitis & IBD shown in exom sequencing of 4602 AS patients; Philip Robinson etal
05 May 2016 Social Spondyloarthritis & Psoriatic arthritis pts (from ARTIS & DANBIO) show NO cancer risk & TNFi does not augment this.
05 May 2016 News Methotrexate Yields No Added Benefit in Etanercept Treated Psoriatic Arthritis Patients
02 May 2016 Social Health Canada approves secukinumab for use in psoriatic arthritis and anklylosing spondylitis
02 May 2016 News Simple Referral Rule May Lead to Earlier Referral and Diagnosis of Axial Spondyloarthritis
29 Apr 2016 Social Extensive skin psoriasis is a risk factor for Psoriatic Arthritis - other risk factors nail dz, obesity & smoking
26 Apr 2016 News Low Adherence to Biologics in Psoriasis Patients
22 Apr 2016 Social Treatment options for active Ankylosing spondylitis: 1) Optimal dose NSAIDs; 2) TNF inhibitor; 3) Secukinumab; 4) ustekinumab (off label)
15 Apr 2016 News Does Psoriasis Increase Risk of Abdominal Aneurysm?
06 Apr 2016 News Tofacitinib Efficacy Revealed in OPAL Study
04 Apr 2016 News Severe Psoriasis Associated with a Renal Disease Risk
31 Mar 2016 News Incidence of Psoriatic Arthritis Among Psoriasis Patients
22 Mar 2016 News FDA Approves Taltz for Psoriasis
22 Mar 2016 Social RT @ArthritisRes: Effectiveness of a second TNFi is significantly impaired in axSpA patients after lack of response to first…